Stay updated on Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedAdded results-related sections (Best Overall Response Rate; Results First Submitted/Posted; Results Reporting Dates; Last Update Posted (Estimated)) and expanded site locations to include New Jersey and New York. Also added the Study Protocol and Statistical Analysis Plan PDF (Revision v3.3.3, 2024-05-03) and removed older entries such as the standalone New Jersey/Ny Locations and earlier Best Overall Response Rate entries.SummaryDifference2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page changed from showing 'No Results Posted' to 'Results Submitted', indicating that results have been submitted for posting.SummaryDifference0.1%

- Check37 days agoChange DetectedPublications section now notes items are auto-filled from PubMed and may not pertain to the study. The revision history updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check44 days agoChange DetectedThe government funding status notice about potential data delays was removed from the page.SummaryDifference0.4%

- Check59 days agoChange DetectedThe new screenshot shows a redesigned layout of the study details page with the same sections and content as before. No substantive data changes observed (enrollment, status, eligibility criteria, or outcomes appear unchanged). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check87 days agoChange DetectedThe page now includes a government funding lapse notice and an updated version tag (v3.2.0), replacing the old v3.1.0.SummaryDifference3%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Salivary Gland Cancer Clinical Trial page.